Is glyphosate (Roundup) a probable human carcinogen?

Why this question matters

Glyphosate has been classified differently by major scientific and regulatory bodies, with some identifying a cancer hazard and others finding that typical approved uses are not expected to pose a cancer risk. The disagreement depends partly on whether the question is about hazard classification, real-world exposure risk, or specific cancer outcomes such as non-Hodgkin lymphoma.

The claim being judged

The claim asks whether glyphosate, best known as the active ingredient in Roundup and many other herbicide products, is a probable human carcinogen. The phrase “probable human carcinogen” is important because it is closely associated with hazard classifications used by some scientific agencies, especially the International Agency for Research on Cancer.

A hazard classification asks whether a substance can cause cancer under some conditions, not necessarily whether typical consumer, agricultural, or dietary exposures are expected to cause cancer. Risk assessments, by contrast, combine hazard evidence with exposure levels and real-world use patterns.

The claim is also complicated because people may use “Roundup” to refer to glyphosate alone, while commercial herbicide formulations can include surfactants and other ingredients. Evidence about pure glyphosate, glyphosate-based formulations, occupational exposure, and dietary residues may not be interchangeable.

What the evidence shows

In 2015, the International Agency for Research on Cancer classified glyphosate as “probably carcinogenic to humans,” Group 2A. IARC cited limited evidence in humans, sufficient evidence in experimental animals, and mechanistic evidence such as genotoxicity and oxidative stress.

Several regulatory agencies have reached different practical conclusions in risk assessments. The U.S. Environmental Protection Agency has stated that glyphosate is not likely to be carcinogenic to humans when used according to labeling, though aspects of EPA’s review have faced legal and scientific scrutiny. European regulators have also generally not classified glyphosate as a carcinogen under their pesticide approval framework, while requiring risk-management conditions.

Epidemiologic studies have focused heavily on agricultural and occupational exposure and on non-Hodgkin lymphoma. Some case-control studies and meta-analyses have reported positive associations, while large cohort data, including the Agricultural Health Study, have generally reported weaker or less consistent associations.

Animal and mechanistic evidence also receives different weight depending on the review framework. IARC’s hazard-oriented approach can give substantial importance to animal and mechanistic findings, while regulatory risk assessments often emphasize dose, exposure, study quality, and consistency across the full toxicology database.

Where uncertainty remains

The largest uncertainty is how to interpret mixed human epidemiology, especially for workers with higher cumulative exposure compared with the general public. Exposure measurement is difficult because studies often rely on self-reported pesticide use, job histories, or broad categories rather than precise individual dose.

Another uncertainty is whether glyphosate-based formulations should be evaluated separately from glyphosate as an isolated chemical. Some laboratory findings suggest formulations may have different biological effects than glyphosate alone, but regulatory testing and exposure standards often focus on the active ingredient.

There is also continuing debate over which decision framework is most relevant to public understanding: hazard classification, regulatory risk assessment, occupational safety assessment, or consumer dietary exposure assessment. These frameworks can produce different-sounding conclusions while addressing different questions.

The three parts of the claim

The umbrella claim is actually several claims bundled into one. Each needs its own evaluation.

Common questions